论文部分内容阅读
儿茶酚胺敏感性室性心动过速(CPVT)是以双向或多形性室性心动过速为特征的遗传性心律失常,多发生于无结构性心脏病的青少年,呈明显的家族聚集性,有常染色体显性和隐性两种遗传形式。目前较成熟的治疗方法有β受体阻滞剂、植入埋藏式心脏转复除颤器、Ⅰ类抗心律失常药及交感神经消融术。随着对CPVT认识的深入,基因和干细胞研究及部分学者提出的迷走神经松弛和心房超速起搏等有望为CPVT治疗提供新的策略。
Catecholamine-sensitive ventricular tachycardia (CPVT) is a hereditary arrhythmia characterized by two-dimensional or pleomorphic ventricular tachycardia, occurs more frequently in adolescents without structural heart disease, showing significant familial aggregation with Autosomal dominant and recessive two genetic forms. At present, more mature treatments include beta blockers, implantable cardioverter defibrillators, type I antiarrhythmic drugs and sympathetic nerve ablation. With the deepening understanding of CPVT, gene and stem cell research and some scholars proposed vagal relaxation and atrial tachycardia pacing is expected to provide a new strategy for CPVT treatment.